Myeloproliferative neoplasm | UniteRare Disease Library

indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated s…

indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events

View Details →FDA Label ↗Patient Assistance ↗

Clinical Trials

20 recruitingView all trials with filters →

Phase 32 trials

Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients with Aspirin Resistance

Phase 3

Actively Recruiting

· Sites: Bangkok Noi, Bangkok · Age: 18–99 yrs

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Phase 3

Actively Recruiting

PI: Toshiaki Sato, MD/PhD (PharmaEssentia JP) · Sites: Chūō, Yamanashi · Age: 18–99 yrs

Phase 23 trials

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Phase 2

Actively Recruiting

PI: Rami Komrokji, MD (Moffitt Cancer Center) · Sites: Tampa, Florida · Age: 18–99 yrs

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Phase 2

Actively Recruiting

PI: Anand A Patel (City of Hope Comprehensive Cancer Center LAO) · Sites: Irvine, California; Orange, California +23 more · Age: 18–99 yrs

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Phase 2

Active

PI: Alessandro Rambaldi, MD (Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, ) · Sites: Berlin; Freiburg im Breisgau +13 more · Age: 18–99 yrs

Other15 trials

Registry of Patients With MPNs in Taiwan

Active

· Sites: Taoyuan District, State · Age: 20–99 yrs

Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)

Active

· Sites: Brest · Age: 18–99 yrs

Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).

Active

· Sites: Alessandria; Asti +23 more · Age: 18–99 yrs

Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)

Actively Recruiting

· Sites: Brest · Age: 0–30 yrs

Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms

Actively Recruiting

PI: Florence Pasquier, MD,PhD (florence.pasquier@gustaveroussy.fr) · Sites: Villejuif, Île-de-France Region · Age: 18–99 yrs

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Actively Recruiting

PI: Anthony F. Shields, MD, PhD (Barbara Ann Karmanos Cancer Institute) · Sites: Detroit, Michigan · Age: 18–120 yrs

Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)

Actively Recruiting

· Sites: Angers; Bayonne +9 more · Age: 18–99 yrs

Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)

Actively Recruiting

· Sites: Bordeaux · Age: 18–99 yrs

Diagnostic Characterization and Evolution of "Triple Negative" Thrombocytosis (CASTETTE)

Active

· Sites: Brest · Age: 18–99 yrs

Evaluation of the Pathobiology of CALR-mutated MPN Cells

Actively Recruiting

PI: Aleksander Chojecki, MD (Atrium Health Levine Cancer) · Sites: Charlotte, North Carolina; Winston-Salem, North Carolina · Age: 18–99 yrs

Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM)

Actively Recruiting

· Sites: Brest · Age: 18–99 yrs

Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy

Active

· Sites: Brest · Age: 18–99 yrs

Unveiling the Germline Predisposition to Myeloproliferative Neoplasms

Actively Recruiting

· Sites: Pavia, Lombardy · Age: 18–99 yrs

MPN Childhood Registry

Actively Recruiting

PI: Axel Karow, MD (Department of Pediatrics and Adolescent Medicine, ) · Sites: Erlangen, Bavaria · Age: 0–17 yrs

Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Study)

Active

· Sites: Pavia, Lombardy · Age: 18–99 yrs

Specialists

Showing 25 of 87View all specialists →

JK

Jean-Jacques Kiladjian

Specialist

Polycythemia vera

PI on 1 active trial3 Myeloproliferative neoplasm publications

Active trials Directions Travel grants

AT

Ayalew Tefferi

ROCHESTER, MN

Specialist

3 Myeloproliferative neoplasm publications

Directions Travel grants

SC

Shayeri Chowdhury

Specialist

2 Myeloproliferative neoplasm publications

Directions Travel grants

RH

Rupen Hargreaves

Specialist

2 Myeloproliferative neoplasm publications

Directions Travel grants

JY

Jie Yang

Specialist

2 Myeloproliferative neoplasm publications

Directions Travel grants

HP

Hélène Pasquer

Specialist

1 Myeloproliferative neoplasm publication

Directions Travel grants

DM

Donal P McLornan

Specialist

2 Myeloproliferative neoplasm publications

Directions Travel grants

RR

Raajit K Rampal

NEW YORK, NY

Specialist

2 Myeloproliferative neoplasm publications

Directions Travel grants

AR

Anita Roy

Specialist

2 Myeloproliferative neoplasm publications

Directions Travel grants

HA

Hassan Alkhateeb

ROCHESTER, MN

Specialist

1 Myeloproliferative neoplasm publication

Directions Travel grants

RH

Robert P Hasserjian

BOSTON, MA

Specialist

1 Myeloproliferative neoplasm publication

Directions Travel grants

AS

Aditi Singh

Specialist

2 Myeloproliferative neoplasm publications

Directions Travel grants

SN

Saadia Naseer

Specialist

2 Myeloproliferative neoplasm publications

Directions Travel grants

SS

Saurabh Shrivastva

Specialist

2 Myeloproliferative neoplasm publications

Directions Travel grants

DT

Douglas Tremblay

NEW YORK, NY

Specialist

2 Myeloproliferative neoplasm publications

Directions Travel grants

CH

Claire Harrison

Specialist

Polycythemia vera

PI on 1 active trial24 Myeloproliferative neoplasm publications

Active trials Directions Travel grants

HM

Hagop Kantarjian, MD

HOUSTON, TX

Specialist

Acute lymphoblastic leukemia Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent Adult T-cell leukemia/lymphoma+6 more

PI on 7 active trials

Active trials Directions Travel grants

NP

Naveen Pemmaraju

HOUSTON, TX

Specialist

Blastic plasmacytoid dendritic cell neoplasm Essential thrombocythemia

PI on 3 active trials10 Myeloproliferative neoplasm publications

Active trials Directions Travel grants

GM

Gabriela Hobbs, MD

BOSTON, MA

Specialist

Essential thrombocythemia Polycythemia vera Primary myelofibrosis

PI on 4 active trials1 Myeloproliferative neoplasm publication

Active trials Directions Travel grants

RS

Rachel B. Salit

SEATTLE, WA

Specialist

Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement Primary myelofibrosis

PI on 4 active trials

Active trials Directions Travel grants

MM

Minocher Battiwalla, MD

NASHVILLE, TN

Specialist

Acute myeloid leukemia Chronic myeloid leukemia Myelodysplastic syndrome+3 more

PI on 2 active trials

Active trials Directions Travel grants

CD

Claire Harrison, Dr

Specialist

Essential thrombocythemia

PI on 1 active trial

Active trials Directions Travel grants

AP

Anthony R Green, Prof

Specialist

Essential thrombocythemia

PI on 1 active trial

Active trials Directions Travel grants

CM

Corey Cutler, MD, MPH

PARK CITY, UT

Specialist

Acute lymphoblastic leukemia Acute myeloid leukemia Bronchiolitis obliterans+5 more

PI on 3 active trials

Active trials Directions Travel grants

FM

Farhad Ravandi-Kashani, MD

HOUSTON, TX

Specialist

Acute lymphoblastic leukemia Acute myeloid leukemia Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent+10 more

PI on 8 active trials

Active trials Directions Travel grants

Treatment Centers

8 centers

⚗️ Trial Site

National Institutes of Health Clinical Center

📍 Bethesda, Maryland

👤 Payal P Khincha, M.D.

👤 Christopher Grunseich, M.D.

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

Financial Resources

1 resources

Agrylin(Anagrelide)— Takeda Development Center Americas, Inc.

Patient Assistance ↗

Travel Grants

No travel grants are currently matched to Myeloproliferative neoplasm.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Myeloproliferative neoplasmForum →

No community posts yet. Be the first to share your experience with Myeloproliferative neoplasm.

Start the conversation →

Latest news about Myeloproliferative neoplasm

Disease timeline:

New recruiting trial: Evaluation of the Pathobiology of CALR-mutated MPN Cells

A new clinical trial is recruiting patients for Myeloproliferative neoplasm

New recruiting trial: P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

A new clinical trial is recruiting patients for Myeloproliferative neoplasm

New recruiting trial: A Trial of Placebo Versus Macrolide for Mycoplasma Pneumoniae Childhood Pneumonia: MYTHIC Study

A new clinical trial is recruiting patients for Myeloproliferative neoplasm

New recruiting trial: Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

A new clinical trial is recruiting patients for Myeloproliferative neoplasm

New recruiting trial: Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN

A new clinical trial is recruiting patients for Myeloproliferative neoplasm

New recruiting trial: Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

A new clinical trial is recruiting patients for Myeloproliferative neoplasm

New recruiting trial: Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

A new clinical trial is recruiting patients for Myeloproliferative neoplasm

New recruiting trial: 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

A new clinical trial is recruiting patients for Myeloproliferative neoplasm

New recruiting trial: MPN Childhood Registry

A new clinical trial is recruiting patients for Myeloproliferative neoplasm

New recruiting trial: Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

A new clinical trial is recruiting patients for Myeloproliferative neoplasm

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Myeloproliferative neoplasm

Are there clinical trials for Myeloproliferative neoplasm?

Yes — 20 recruiting clinical trials are currently listed for Myeloproliferative neoplasm on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Myeloproliferative neoplasm?

25 specialists and care centers treating Myeloproliferative neoplasm are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Myeloproliferative neoplasm?

1 patient support program are currently tracked on UniteRare for Myeloproliferative neoplasm. See the treatments and support programs sections for copay assistance, eligibility, and contact details.